Judson I - Search Results

1

Prognostic factors for primary gastrointestinal stromal tumours: are they the same in the multidisciplinary treatment era?

Cananzi FC, Lorenzi B, Belgaumkar A, Benson C, Judson I, Mudan S. Cananzi FC, et al. Among authors: judson i. Langenbecks Arch Surg. 2014 Mar;399(3):323-32. doi: 10.1007/s00423-014-1160-3. Epub 2014 Jan 12. Langenbecks Arch Surg. 2014. PMID: 24413830

2

Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread.

Burkill GJ, Badran M, Al-Muderis O, Meirion Thomas J, Judson IR, Fisher C, Moskovic EC. Burkill GJ, et al. Radiology. 2003 Feb;226(2):527-32. doi: 10.1148/radiol.2262011880. Radiology. 2003. PMID: 12563150

3

Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group.

Judson I, Ma P, Peng B, Verweij J, Racine A, di Paola ED, van Glabbeke M, Dimitrijevic S, Scurr M, Dumez H, van Oosterom A. Judson I, et al. Cancer Chemother Pharmacol. 2005 Apr;55(4):379-386. doi: 10.1007/s00280-004-0876-0. Epub 2004 Dec 9. Cancer Chemother Pharmacol. 2005. PMID: 15592836

4

Surgery for gastrointestinal stromal tumour in the post-imatinib era.

Neuhaus SJ, Clark MA, Hayes AJ, Thomas JM, Judson I. Neuhaus SJ, et al. Among authors: judson i. ANZ J Surg. 2005 Mar;75(3):165-72. doi: 10.1111/j.1445-2197.2005.03326.x. ANZ J Surg. 2005. PMID: 15777399 Review.

5

The development and application of imatinib.

Jones RL, Judson IR. Jones RL, et al. Expert Opin Drug Saf. 2005 Mar;4(2):183-91. doi: 10.1517/14740338.4.2.183. Expert Opin Drug Saf. 2005. PMID: 15794712 Review.

6

Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.

Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I. Karavasilis V, et al. Among authors: judson i. Cancer. 2008 Apr 1;112(7):1585-91. doi: 10.1002/cncr.23332. Cancer. 2008. PMID: 18278813 Free article.

7

Imatinib in advanced gastrointestinal stromal tumour: when is 800 mg the correct dose?

Judson I. Judson I. Curr Opin Oncol. 2008 Jul;20(4):433-7. doi: 10.1097/CCO.0b013e328302ed96. Curr Opin Oncol. 2008. PMID: 18525340 Review.

8

Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma.

Jones RL, McCall J, Adam A, O'Donnell D, Ashley S, Al-Muderis O, Thway K, Fisher C, Judson IR. Jones RL, et al. Among authors: judson ir. Eur J Surg Oncol. 2010 May;36(5):477-82. doi: 10.1016/j.ejso.2009.12.005. Epub 2010 Jan 8. Eur J Surg Oncol. 2010. PMID: 20060679

9

The safety profile of imatinib in CML and GIST: long-term considerations.

Thanopoulou E, Judson I. Thanopoulou E, et al. Among authors: judson i. Arch Toxicol. 2012 Jan;86(1):1-12. doi: 10.1007/s00204-011-0729-7. Epub 2011 Jun 30. Arch Toxicol. 2012. PMID: 21717109 Review.

10

Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.

Cassier PA, Fumagalli E, Rutkowski P, Schöffski P, Van Glabbeke M, Debiec-Rychter M, Emile JF, Duffaud F, Martin-Broto J, Landi B, Adenis A, Bertucci F, Bompas E, Bouché O, Leyvraz S, Judson I, Verweij J, Casali P, Blay JY, Hohenberger P; European Organisation for Research and Treatment of Cancer. Cassier PA, et al. Among authors: judson i. Clin Cancer Res. 2012 Aug 15;18(16):4458-64. doi: 10.1158/1078-0432.CCR-11-3025. Epub 2012 Jun 20. Clin Cancer Res. 2012. PMID: 22718859

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

393 results

Search Page

Filters